Australasian Journal of Dermatology provides the latest peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology.
Featured Article
Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting
Peter Foley, Yves A. Kerdraon, John P. Hogden, Stephen Shumack, Lynda Spelman, Deshan Sebaratnam, Charles S. Su, Constance H. Katelaris
Dupilumab-associated ocular surface disease (DAOSD) is of relevance in patients with atopic dermatitis (AD). Guidance on DAOSD assessment and management in the Australian setting is needed to reduce its impact and minimise disruption to treatment.
A systematic review of the literature was undertaken to understand the epidemiology, pathophysiology, risk factors for DAOSD, and to inform an interdisciplinary decision framework guide the recognition and management of DAOSD .
The study found that DAOSD usually develops within four months of starting dupilumab, with the occurrence of new cases decreasing over time. The reported incidence of DAOSD varies depending on the nature and source of data, ranging from 8.6% to 22.1% in clinical trials and from 0.5% to 70% in real-world data. Occurrence of DAOSD is more common in patients with severe AD and a history of ocular disease. Pathophysiology is still to be fully understood. Management options include medications such as lubricants/artificial tears, corticosteroids, calcineurin inhibitors, antihistamines, anti-inflammatory agents and antimicrobial agents. Current therapies aim to relieve symptoms or reduce severity to a tolerable level that allows for continued use of dupilumab.
It was suggested that recommendations for DAOSD include identification of high-risk patients, vigilance for red flags (keratoconus, herpetic and bacterial keratitis), regular assessment of symptom severity and collaborative interdisciplinary management and care, with the aim to reduce the impact of DAOSD and minimise disruption to dupilumab therapy.
About the Journal
The Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society. Editorially independent and peer-reviewed, the journal showcases the latest in dermatology research and innovation.
With four issues a year and special editions, the journal covers clinical presentations, medical and physical therapies and investigations, including dermatopathology, mycology, dermoscopy, surgery and contact dermatitis.
2022 Journal metrics
Accessing the Journal
ACD Members
ACD members have complimentary access to the AJD. Members can access the journal by logging into the Members only section of College’s website and selecting ‘My Online Journals’.
Other Readers
Browse contents, abstracts and subscribe here.
Editorial Board
Professor Kiarash Khosrotehrani
Institute of Molecular Bioscience, The University of Queensland Diamantina Institute, Brisbane, Australia.
Associate Professor Helmut Schaider
Dermatology Research Centre, School of Medicine, University of Queensland, Brisbane, Australia.
Professor Khosrotehrani is a clinician-scientist, practicing dermatologist with a focus on delivering state of the art concept and technologies to real-world clinical problems. A Fellow of the Australasian College of Dermatologists (ACD), he leads the Experimental Dermatology Group at the University of Queensland Diamantina Institute in Brisbane, Australia; is deputy director of the Australian Skin and Skin Cancer Research Centre in Brisbane and practises at the Princess Alexandra Hospital and the Skin and Cancer Foundation’s Queensland Institute of Dermatology. Passionate about the development of academic medicine and future academic clinicians, he is chair of ACD’s Academic Research Committee, President of the Australasian Society for Dermatology Research and a board member of the International Society for Investigative Dermatology. He obtained his MD in Paris, France specialising in Dermatology and is a former graduate of the Ecole Normale Supérieure and the Institut Pasteur of Paris (Université Paris VI, Pierre et Marie Curie) obtaining a PhD in Physiology and Physiopathology. He completed his post-doctoral training in stem cell biology and clinical genetics at Tufts-New England Medical Centre in Boston, USA. Acknowledged by the National Health and Medical Research Council (NHMRC) of Australia through an achievement award (2011) and an NHMRC excellence award (2016), his research is fundamentally based on regenerative medicine concepts applied at basic, translational and clinical levels to melanoma, keratinocyte cancers and skin wounds and takes a multidisciplinary approach. This unique expertise and leadership in research is witnessed by a record of highly cited articles (over 3700 citations, H index 33). | Associate Professor Schaider is an academic dermatologist recognised as a clinical researcher in skin cancer focusing on melanoma biology and early detection of melanoma. He is a Fellow of the Australasian College of Dermatologists, Treasurer of the Australasian Society of Dermatology Research and is practising at the Sunshine Coast University Hospital and the Princess Alexandra Hospital, Brisbane. He obtained his medical degree at the Medical University of Graz, Austria, and received training as a postdoctoral researcher in pharmacology at the German Cancer Research Centre, Heidelberg, Germany and melanoma biology at The Wistar Institute, Philadelphia, US. After relocating to Australia, he set up an independent research group at the Translational Research Institute, Brisbane aiming to identify novel targets tackling cancer drug resistance and improving early detection of melanoma. His group recently identified a chronic stress induced drug tolerant phenotype in cancer and found a novel potential druggable target. Early detection of melanoma is utilizing cutting edge technology like 3D whole body photography to develop surveillance programs for high-risk patients. |
| Dr Nikki Adler | Monash University, Melbourne, Australia |
| Dr Keng Chen | Sable Dermatology, Sydney, Australia |
| Dr Peggy Chen | Taranaki District Health Board, New Plymouth, New Zealand |
| Dr Harriet Cheng | Auckland City Hospital, Auckland |
| Dr Karen Cheung | The Skin Hospital, Sydney, Australia |
| Dr Haady Fallah | Concord Repatriation General Hospital, Sydney, Australia |
| Dr Esther Hong | Royal North Shore Hospital of Sydney, Sydney, Australia |
| Dr Joseph Konya | The Skin Hospital, Sydney, Australia |
| Prof Prasad Kumarasinghe | Fiona Stanley Hospital, Perth, Australia |
| A/Prof Christopher McCormack | Peter MacCallum Cancer Centre, Melbourne Australia |
| Dr Anne O’Neill | The Children’s Hospital at Westmead, Sydney Australia |
| Dr David Orchard | Private Suites Royal Children’s Hospital, Melbourne, Australia |
| Dr Yan Pan | Victorian Melanoma Service, Alfred Hospital, VIC, Australia |
| A/Prof Helmut Schaider | Dermatology Research Centre, The University of Queensland Diamantina Institute, Brisbane, Australia |
| A/Prof Stephen Shumack | Royal North Shore Hospital of Sydney, Sydney, Australia |
| Prof Rodney Sinclair | University of Melbourne and Epworth Hospital, Melbourne, Australia |
| Prof H Peter Soyer | Dermatology Research Centre, The University of Queensland Diamantina Institute, Brisbane, Australia |
| Dr Keng-Ee Thai | Royal Australian Army Medical Corps |
| Dr Orli Wargon | Sydney Children’s Hospital, Sydney, Australia |
| Dr Ashfaq Marghoob | Memorial Sloan Kettering Skin Cancer Center, New York, NY, USA |
| Prof John McGrath | St John’s Institute of Dermatology, London, United Kingdom |
| Dr Masaru Tanaka | Tokyo Woman’s Medical University, Medical Center East, Tokyo, Japan |
| Dr Mark Tang | National Skin Centre, Singapore |
| Dr Clark C Otley | Mayo Clinic, Rochester, USA |
